Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
47
TAK Quote, Financials, Valuation and Earnings
Last price:
$14.28
Seasonality move
:
5.02%
Day range:
$14.26 - $14.42
52-week range:
$12.80 - $15.69
Dividend yield:
4.65%
P/E ratio:
181.60x
P/S ratio:
1.54x
P/B ratio:
0.94x
Volume:
2.1M
Avg. volume:
3M
1-year change:
4.46%
Market cap:
$45.2B
Revenue:
$30.1B
EPS (TTM):
$0.08
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$7.8B | -- | -1.44% | -- | $17.76 |
|
BMY
Bristol Myers Squibb Co.
|
$11.8B | $1.52 | -0.74% | 4553.59% | $53.41 |
|
JNJ
Johnson & Johnson
|
$23.8B | $2.76 | 7.15% | 79.1% | $202.54 |
|
NVS
Novartis AG
|
$13.9B | $2.31 | 4.45% | 37.94% | $134.88 |
|
PFE
Pfizer Inc.
|
$16.5B | $0.63 | -1.98% | 745.84% | $29.04 |
|
SNY
Sanofi
|
$14.2B | $1.57 | -6.06% | 28.6% | $60.13 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$14.31 | $17.76 | $45.2B | 181.60x | $0.34 | 4.65% | 1.54x |
|
BMY
Bristol Myers Squibb Co.
|
$51.95 | $53.41 | $105.8B | 17.54x | $0.62 | 4.77% | 2.20x |
|
JNJ
Johnson & Johnson
|
$205.33 | $202.54 | $494.7B | 19.82x | $1.30 | 2.5% | 5.40x |
|
NVS
Novartis AG
|
$133.72 | $134.88 | $256.6B | 18.24x | $3.99 | 2.99% | 4.84x |
|
PFE
Pfizer Inc.
|
$25.57 | $29.04 | $145.4B | 14.90x | $0.43 | 6.73% | 2.32x |
|
SNY
Sanofi
|
$49.69 | $60.13 | $121.2B | 12.41x | $2.20 | 4.42% | 2.86x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
39.45% | -0.605 | 68.02% | 0.64x |
|
BMY
Bristol Myers Squibb Co.
|
73.34% | -0.073 | 56.92% | 0.94x |
|
JNJ
Johnson & Johnson
|
36.62% | 0.235 | 10.26% | 0.71x |
|
NVS
Novartis AG
|
41.94% | 0.086 | 12.99% | 0.58x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
|
SNY
Sanofi
|
22.66% | -0.244 | -- | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$3.6B | $763.2M | 0.33% | 0.55% | 10.11% | $2B |
|
BMY
Bristol Myers Squibb Co.
|
$8.1B | $3.8B | 8.82% | 34.7% | 31.46% | $6B |
|
JNJ
Johnson & Johnson
|
$16.7B | $7.1B | 20.94% | 33.27% | 29.64% | $8B |
|
NVS
Novartis AG
|
$10.3B | $4.2B | 19.37% | 33.87% | 30.24% | $5.7B |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
|
SNY
Sanofi
|
$8.8B | $1.9B | 9.89% | 12.45% | 14.08% | $218.7M |
Takeda Pharmaceutical Co., Ltd. vs. Competitors
-
Which has Higher Returns TAK or BMY?
Bristol Myers Squibb Co. has a net margin of -1.05% compared to Takeda Pharmaceutical Co., Ltd.'s net margin of 17.96%. Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55% beat Bristol Myers Squibb Co.'s return on equity of 34.7%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B BMYBristol Myers Squibb Co.66% $1.08 $69.6B -
What do Analysts Say About TAK or BMY?
Takeda Pharmaceutical Co., Ltd. has a consensus price target of $17.76, signalling upside risk potential of 23.91%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $53.41 which suggests that it could grow by 2.81%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Bristol Myers Squibb Co., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Bristol Myers Squibb Co..
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical Co., Ltd.3 0 0 BMYBristol Myers Squibb Co.3 20 1 -
Is TAK or BMY More Risky?
Takeda Pharmaceutical Co., Ltd. has a beta of 0.027, which suggesting that the stock is 97.262% less volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.363%.
-
Which is a Better Dividend Stock TAK or BMY?
Takeda Pharmaceutical Co., Ltd. has a quarterly dividend of $0.34 per share corresponding to a yield of 4.65%. Bristol Myers Squibb Co. offers a yield of 4.77% to investors and pays a quarterly dividend of $0.62 per share. Takeda Pharmaceutical Co., Ltd. pays 242.25% of its earnings as a dividend. Bristol Myers Squibb Co. pays out 54.44% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical Co., Ltd.'s is not.
-
Which has Better Financial Ratios TAK or BMY?
Takeda Pharmaceutical Co., Ltd. quarterly revenues are $7.5B, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.2B. Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M is lower than Bristol Myers Squibb Co.'s net income of $2.2B. Notably, Takeda Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 181.60x while Bristol Myers Squibb Co.'s PE ratio is 17.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical Co., Ltd. is 1.54x versus 2.20x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical Co., Ltd.1.54x 181.60x $7.5B -$79.5M BMYBristol Myers Squibb Co.2.20x 17.54x $12.2B $2.2B
-
Which has Higher Returns TAK or JNJ?
Johnson & Johnson has a net margin of -1.05% compared to Takeda Pharmaceutical Co., Ltd.'s net margin of 21.47%. Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55% beat Johnson & Johnson's return on equity of 33.27%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B JNJJohnson & Johnson69.72% $2.12 $125.1B -
What do Analysts Say About TAK or JNJ?
Takeda Pharmaceutical Co., Ltd. has a consensus price target of $17.76, signalling upside risk potential of 23.91%. On the other hand Johnson & Johnson has an analysts' consensus of $202.54 which suggests that it could fall by -1.36%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Johnson & Johnson, analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Johnson & Johnson.
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical Co., Ltd.3 0 0 JNJJohnson & Johnson9 11 0 -
Is TAK or JNJ More Risky?
Takeda Pharmaceutical Co., Ltd. has a beta of 0.027, which suggesting that the stock is 97.262% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.
-
Which is a Better Dividend Stock TAK or JNJ?
Takeda Pharmaceutical Co., Ltd. has a quarterly dividend of $0.34 per share corresponding to a yield of 4.65%. Johnson & Johnson offers a yield of 2.5% to investors and pays a quarterly dividend of $1.30 per share. Takeda Pharmaceutical Co., Ltd. pays 242.25% of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical Co., Ltd.'s is not.
-
Which has Better Financial Ratios TAK or JNJ?
Takeda Pharmaceutical Co., Ltd. quarterly revenues are $7.5B, which are smaller than Johnson & Johnson quarterly revenues of $24B. Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M is lower than Johnson & Johnson's net income of $5.2B. Notably, Takeda Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 181.60x while Johnson & Johnson's PE ratio is 19.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical Co., Ltd. is 1.54x versus 5.40x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical Co., Ltd.1.54x 181.60x $7.5B -$79.5M JNJJohnson & Johnson5.40x 19.82x $24B $5.2B
-
Which has Higher Returns TAK or NVS?
Novartis AG has a net margin of -1.05% compared to Takeda Pharmaceutical Co., Ltd.'s net margin of 28.26%. Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55% beat Novartis AG's return on equity of 33.87%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B NVSNovartis AG74.59% $2.02 $76.8B -
What do Analysts Say About TAK or NVS?
Takeda Pharmaceutical Co., Ltd. has a consensus price target of $17.76, signalling upside risk potential of 23.91%. On the other hand Novartis AG has an analysts' consensus of $134.88 which suggests that it could grow by 0.87%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Novartis AG, analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Novartis AG.
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical Co., Ltd.3 0 0 NVSNovartis AG1 6 2 -
Is TAK or NVS More Risky?
Takeda Pharmaceutical Co., Ltd. has a beta of 0.027, which suggesting that the stock is 97.262% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.525, suggesting its less volatile than the S&P 500 by 47.542%.
-
Which is a Better Dividend Stock TAK or NVS?
Takeda Pharmaceutical Co., Ltd. has a quarterly dividend of $0.34 per share corresponding to a yield of 4.65%. Novartis AG offers a yield of 2.99% to investors and pays a quarterly dividend of $3.99 per share. Takeda Pharmaceutical Co., Ltd. pays 242.25% of its earnings as a dividend. Novartis AG pays out 55.39% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical Co., Ltd.'s is not.
-
Which has Better Financial Ratios TAK or NVS?
Takeda Pharmaceutical Co., Ltd. quarterly revenues are $7.5B, which are smaller than Novartis AG quarterly revenues of $13.9B. Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M is lower than Novartis AG's net income of $3.9B. Notably, Takeda Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 181.60x while Novartis AG's PE ratio is 18.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical Co., Ltd. is 1.54x versus 4.84x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical Co., Ltd.1.54x 181.60x $7.5B -$79.5M NVSNovartis AG4.84x 18.24x $13.9B $3.9B
-
Which has Higher Returns TAK or PFE?
Pfizer Inc. has a net margin of -1.05% compared to Takeda Pharmaceutical Co., Ltd.'s net margin of 21.32%. Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About TAK or PFE?
Takeda Pharmaceutical Co., Ltd. has a consensus price target of $17.76, signalling upside risk potential of 23.91%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13.57%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Pfizer Inc., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical Co., Ltd.3 0 0 PFEPfizer Inc.7 15 1 -
Is TAK or PFE More Risky?
Takeda Pharmaceutical Co., Ltd. has a beta of 0.027, which suggesting that the stock is 97.262% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock TAK or PFE?
Takeda Pharmaceutical Co., Ltd. has a quarterly dividend of $0.34 per share corresponding to a yield of 4.65%. Pfizer Inc. offers a yield of 6.73% to investors and pays a quarterly dividend of $0.43 per share. Takeda Pharmaceutical Co., Ltd. pays 242.25% of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TAK or PFE?
Takeda Pharmaceutical Co., Ltd. quarterly revenues are $7.5B, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Takeda Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 181.60x while Pfizer Inc.'s PE ratio is 14.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical Co., Ltd. is 1.54x versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical Co., Ltd.1.54x 181.60x $7.5B -$79.5M PFEPfizer Inc.2.32x 14.90x $16.7B $3.6B
-
Which has Higher Returns TAK or SNY?
Sanofi has a net margin of -1.05% compared to Takeda Pharmaceutical Co., Ltd.'s net margin of 36.7%. Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55% beat Sanofi's return on equity of 12.45%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B SNYSanofi72.13% $1.83 $106.5B -
What do Analysts Say About TAK or SNY?
Takeda Pharmaceutical Co., Ltd. has a consensus price target of $17.76, signalling upside risk potential of 23.91%. On the other hand Sanofi has an analysts' consensus of $60.13 which suggests that it could grow by 21.01%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Sanofi, analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Sanofi.
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical Co., Ltd.3 0 0 SNYSanofi5 2 0 -
Is TAK or SNY More Risky?
Takeda Pharmaceutical Co., Ltd. has a beta of 0.027, which suggesting that the stock is 97.262% less volatile than S&P 500. In comparison Sanofi has a beta of 0.446, suggesting its less volatile than the S&P 500 by 55.394%.
-
Which is a Better Dividend Stock TAK or SNY?
Takeda Pharmaceutical Co., Ltd. has a quarterly dividend of $0.34 per share corresponding to a yield of 4.65%. Sanofi offers a yield of 4.42% to investors and pays a quarterly dividend of $2.20 per share. Takeda Pharmaceutical Co., Ltd. pays 242.25% of its earnings as a dividend. Sanofi pays out 66.53% of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical Co., Ltd.'s is not.
-
Which has Better Financial Ratios TAK or SNY?
Takeda Pharmaceutical Co., Ltd. quarterly revenues are $7.5B, which are smaller than Sanofi quarterly revenues of $12.2B. Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M is lower than Sanofi's net income of $4.5B. Notably, Takeda Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 181.60x while Sanofi's PE ratio is 12.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical Co., Ltd. is 1.54x versus 2.86x for Sanofi. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical Co., Ltd.1.54x 181.60x $7.5B -$79.5M SNYSanofi2.86x 12.41x $12.2B $4.5B
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
39
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
